Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients. (1980).
Author(s): Jormar M. Cunhu, E.A. Carlini, Aparecido E. Pereira, Oswaldo L. Ramos, Camilo Pimentel, Rubens Gagliardi. W.L. Sanvito, N. Lander and R. Mechoulam. According to the results of this study, cannabidiol (CBD) has the potential to become an antiepileptic drug, as well as having a possible potentiating effect on other antiepileptic drugs. It was found that CBD has a beneficial effect in patients with secondary generalized epilepsy with temporal focus. View study
Epidiolex (Cannabidiol) in Treatment Resistant Epilepsy. (2015).
Author(s): Orrin Devinsky, Joseph Sullivan, Daniel Friedman, Elizabeth Thiele, Eric Marsh, Linda Laux, Ian Miller, Robert Flamini, Angus Wilfong, Francis Filloux, Matthew Wong, Nicole Tilton, Patricia Bruno, Rebecca Kamens, Jane Maclean, Judith Bluvstein, Srishti Nangia, Anup Patel, Maria Roberta Cilio. This study has obtained promising results for Epidiolex (cannabidiol) as a drug for treatment in children with a variety of epilepsy syndromes. It was found that children and young adults with Dravet’s syndrome had the greatest reduction in seizures. More randomized controlled trials are being conducted to support these results. View study
Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. (2002).
Author(s): Melisa J. Wallace, Billy R. Martin, Robert J. DeLorenzo. The cannabinoids Anandamida and its analog, O-1812, have been shown to be effective anticonvulsants in animal models, further evidencing that the cannabinoid receptor CB1 is one of the main mediators of the modulation of seizures. View study
On the application of cannabis in paediatrics and epileptology. (2004).
Author(s): Rüdiger Lorenz. A study about the therapeutic application of THC in children and adolescents with neurodegenerative diseases, epilepsy and other chronic conditions, showed that THC reduced spasticity, provoked improved dystonia, and had anticonvulsive actions. View study
Marijuana Use in Epilepsy: The Myth and the Reality. (2015).
Author(s): Kamil Detyniecki & Lawrence Hirsch. In recent years the interest for the use of cannabinoids for the treatment of epilepsy has grown. This review answers the most significant questions that doctors have about the use of cannabis in the treatment of epilepsy. View study
Redistribution of CB1 Cannabinoid Receptors in the Acute and Chronic Phases of Pilocarpine-Induced Epilepsy. (2011).
Author(s): Maria R. Karlocai, Kinga Toth, Masahiko Watanabe, Catherine Ledent, Gabor Juhasz, Tamas F. Freund, Zsofia Magloczky. The endogenous cannabinoid system plays a fundamental role in retrograde synaptic communication and controls the propagation of activity in an epileptic network. Changes in the pattern of CB1 cannabinoid receptor expression are associated with the severity of the hippocampal lesion, caused by acute seizures that eventually lead to sclerosis. View study
Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. (2013).
Author(s): Brenda E. Porter and Catherine Jacobson. This study is based on a survey that shows that parents are using cannabis enriched with CBD for the treatment of severe epilepsy in children, and the beneficial effects of this treatment. View study
The case for assessing cannabidiol in epilepsy. (2014).
Author(s): Maria Roberta Cilio, Elizabeth A. Thiele, and Orrin Devinsky. Pure CBD (the main non-psychotropic compound of Cannabis sativa), due to its anticonvulsant properties, seems to be an ideal candidate as therapy for epilepsy resistant to conventional treatment. View study
The case for medical marijuana in epilepsy. (2014).
Author(s): Edward Maa and Paige Figi. Charlotte is a girl with Dravet syndrome who appeared in a special on CNN. She started a CBD: THC therapy in parallel with her conventional treatment and experienced an extraordinary reduction in the frequency of her seizures. View study
The current status of artisanal cannabis for the treatment of epilepsy in the United States. (2017).
Author(s): Dustin Sulak, Russell Saneto, Bonni Goldstein. This study presents data on the efficacy and adverse effects of artisanal cannabis in patients with epilepsy in the states of Washington, California and Maine. View study
The Endogenous Cannabinoid System Regulates Seizure Frequency and Duration in a Model of Temporal Lobe Epilepsy. (2003).
Author(s): Melisa J. Wallace, Robert E. Blair, Katherine W. Falenski, Billy R. Martin, and Robert J. Delorenzo. These studies demonstrate the role of the endogenous cannabinoid system in the regulation of seizure activity and the modulation of neuroexitation, which demonstrates the potential of cannabinoids as anticonvulsants. View study
The Pharmacological Basis of Cannabis Therapy for Epilepsy. (2016).
Author(s): Doodipala Samba Reddy and Victoria M. Golub. Essay on the pharmacological and therapeutic fundamentals of cannabis, with a focus on the endocannabinoid mechanisms underlying the emerging neurotherapeutics of CBD in epilepsy. View study
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. (2017).
Author(s): Orrin Devinsky, Helen Cross, Linda Laux, Eric Marsh, Ian Miller, Rima Nabbout, Ingrid E. Scheffer, Elizabeth A. Thiele and Stephen Wright. In this study, cannabidiol was used to treat seizures in patients with Dravet syndrome, and resulted in a greater reduction in seizure frequency. View study
Author(s): James Jeffrey Bradstreet. Dr. James Bradstreet, an experienced and respected physician in the treatment of autism, epilepsy and associated disorders, indicates that cannabinoids can treat epilepsy. CBD and THC are effective in cases of epilepsy resistant to conventional treatments. View study
Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se. (2014).
Author(s): Andrew J Hill, PhD. Cannabidiol is a non-psychoactive cannabinoid, well tolerated and anticonvulsant. Here, we investigate the effects of CBD and the structurally similar cannabinoid cannabigerol (CBG), where CBG had no effect on seizures induced in animal models. View study
Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis. (2011).
Author(s): Daniele De Filippis, Giuseppe Esposito, Carla Cirillo , Mariateresa Cipriano, Benedicte Y. De Winter, Caterina Scuderi, Giovanni Sarnelli, Rosario Cuomo, Luca Steardo, Joris G. De Man, Teresa Iuvone. Cannabidiol (CBD) due to its ability to control reactive gliosis in the central nervous system but without the psychotropic effects, can be a new therapeutic alternative in the treatment of inflammatory bowel diseases. View study
Cannabis Alleviates Symptoms Of Crohn’s Disease. (2005).
Author(s): Jeff Hergenrather. A pilot study conducted in patients with Crohn’s disease, who underwent treatment with cannabis, reported numerous benefits, such as reduction of: vomiting, depression, nausea, pain and fatigue; as well as an improvement in appetite and activity. View study
Cannabis Finds Its Way into Treatment of Crohn’s Disease. (2013).
Author(s): Rudolf Schicho, Martin Storr. For a long time in traditional medicine, cannabis has been used for the treatment of intestinal diseases. This article shows that the cannabis sativa is highly efficient and has a great therapeutic potential to alleviate the inflammations and affections of this disease. View study
Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis. (2011).
Author(s): Daniele De Filippis1,5., Giuseppe Esposito2., Carla Cirillo3, Mariateresa Cipriano1,5, Benedicte Y. DeWinter4, Caterina Scuderi2, Giovanni Sarnelli3, Rosario Cuomo3 , Luca Steardo2 , Joris G. De Man4 , Teresa Iuvone1,5*. Cannabidiol (CBD) due to its ability to control reactive gliosis in the central nervous system but without the psychotropic effects, can be a new therapeutic alternative in the treatment of inflammatory bowel diseases. View study
Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival. (2012).
Author(s): Jahan P. Marcu, Rigel T. Christian, Darryl Lau, Anne J. Zielinski, Maxx P. Horowitz, Jasmine Lee, Arash Pakdel, Juanita Allison, Chandani Limbad, Dan H. Moore, Garret L. Yount, Pierre-Yves Desprez, and Sean D. McAllister. Adding cannabidiol to Δ9-THC may improve the effectiveness of Δ9-THC in the treatment of glioblastoma in patients with cancer. When treating the cells with both compounds it was observed that these acted synergistically to inhibit cell proliferation. View study
Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget Effect. (2013).
Author(s): Marta Solinas, Paola Massi , Valentina Cinquina, Marta Valenti, Daniele Bolognini, Marzia Gariboldi, Elena Monti, Tiziana Rubino, Daniela Parolaro. CBD is a non-psychoactive phytocannabinoid and also very efficient to treat multiple tumor characteristics. By not having side effects, it is very possible that it can be used as an effective drug against cancer. View study
Medical use of cannabis in patients with HIV/AIDS. (2013).
Author(s): Elizabeth E Lutge, Andy Gray, Nandi Siegfried. Cannabis can help in the treatment of AIDS-related anorexia, and is said to improve appetite, which results in weight gain and better mood, thus improving the quality of life. View study
Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function. (2012).
Author(s): V. Cinquina f , A. Gómez a , R. Layunta a , M. Santos a , J. Fernández-Ruiz, José Martínez-Orgado. CBD has been shown to have short-term neuroprotective effects in the immature brain, suggesting that it could be used as a neuroprotective agent for neonatal hypoxiaeischemia. View study